Dihydropteroate synthase inhibitor explained

Dihydropteroate synthase inhibitors are drugs that inhibit the action of dihydropteroate synthase. They include sulfonamides, dapsone, and para-aminosalicylic acid.[1]

In bacteria, antibacterial sulfonamides act as competitive inhibitors of the enzyme dihydropteroate synthase, DHPS. DHPS catalyses the conversion of PABA (para-aminobenzoate) to dihydropteroate, a key step in folate synthesis.[2] Folate is necessary for the cell to synthesize nucleic acids (nucleic acids are essential building blocks of DNA and RNA), and in its absence cells will be unable to divide. Hence the sulfonamide antibacterials exhibit a bacteriostatic rather than bactericidal effect.[3]

Uses

Folate is not synthesized in mammalian cells, but is instead a dietary requirement. This explains the selective toxicity to bacterial cells of these drugs. These antibiotics are used to treat Pneumocystis jirovecii pneumonia, urinary tract infections, and shigellosis.

Notes and References

  1. Book: Goodman and Gilmans The Pharmacological Basis of Therapeutics . 26 October 2017 . 13th . McGraw Hill Education . 9781259584749 . 1078.
  2. Book: Bauman, Robert W. . Microbiology: With Diseases by Body System . Boston . 2015 . 4th . Pearson . 9780321918550 . 296.
  3. Web site: Sulfonamides and Sulfonamide Combinations . Merck Veterinary Manual . 2017-06-18 .